Abstract:OBJECTIVE:To study the effect of co-blockage of vascular endothelial growth factor (VEGF) and its receptor (KDR) on growth of bladder carcinoma T24 cells and nude mice xenograft.METHODS:T24 cell line co-transfected with VEGF siRNA and sKDR expression plasmids was developed and its proliferation was assayed by MTT and apoptosis by FCM. The nude mice model bearing bladder carcinoma xenograft was established. The tumor cell VEGF expression, stroma microvessel density (MVD) and tumor cell topoisomerase II alpha (Topo II alpha) expression were detected by immunohistochemistry. Cell apoptosis was estimated by TUNEL assay.RESULTS:MTT assay showed that cell proliferation in VEGF siRNA, sKDR and combination groups was 56.3% +/- 8.3%, 42.6% +/- 13.8% and 32.5% +/- 4.3%, respectively, significantly lower than that in the scramble control (97.3% +/- 11.6%, P < 0.0001). FCM showed there were sub-diploid apoptotic peaks before G1 phase in VEGF siRNA, sKDR and combination groups, and apoptosis ratio was 5.1% +/- 0.9%, 4.2% +/- 0.5% and 8.8% +/- 0.7%, respectively, all of which were higher than that in the scramble control (0.9% +/- 0.4%, P < 0.05), and the combination group had even more higher apoptosis than the two singlely treated groups (P < 0.01). In vivo test showed that tumor growth was inhibited in VEGF siRNA, sKDR and combination groups, and from day 16 the tumor volume in combination group was significantly smaller than that in scramble control (P < 0.05), and from day 28 the tumor almost lost the ability to further growth. Immunohistochemistry revealed VEGF expression in combination group was 54.37 +/- 5.28, significantly lower than that in the scramble control (141.66 +/- 8.59, P < 0.0001). MVD number was only 8.22 +/- 3.79, much less compared with that in the scramble control (61.76 +/- 5.28, P < 0.0001) or sKDR group (19.46 +/- 4.16, P = 0.0089). Tumor cell proliferation index in the combination group (1.5% +/- 0.7%) was significantly decreased compared with that in the scramble control (11.8% +/- 5.2%, P < 0.0001), and apoptosis index (67.2% +/- 8.5%) was much higher than that in the scramble control (8.7% +/- 2.7%, P < 0.0001), VEGF siRNA group (54.3% +/- 4.8%, P = 0.0492) or sKDR group (52.3% +/- 6.4%, P = 0.0293).CONCLUSION:VEGF siRNA or sKDR alone can inhibit tumor cell proliferation and induce cell apoptosis, but co-blockage of VEGF and KDR by their combination shows more significant therapeutic efficacy.

Inhibition of Ovarian Tumor Growth by Gene Therapy with Recombinant Soluble Vascular Endothelial Growth Factor Receptor 2.

Gene Therapeutic Exploration: Retrovirus-Mediated Soluble Vascular Endothelial Growth Factor Receptor-2 (Sflk-1) Inhibits the Tumorigenicity of S180, Mcf-7, and B16 Cells in Vivo

Inhibitory Effect of 2'-O-methoxyethyl-modified Antisense Oligonucleotides Targeting Vascular Endothelial Growth Factor A on SKOV3 Human Ovarian Cancer Cells.

Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor.

Systemic Inhibition of Tumor Growth by Soluble Flk-1 Gene Therapy Combined with Cisplatin

VEGF-targeted short hairpin RNA inhibits intraperitoneal ovarian cancer growth in nude mice.

[Effect of VEGFR1 Gene Silencing by Shrna on Proliferation, Migration and Apoptosis of U937 Line].

[Cloning, Expression of Soluble VEGFR2 Fragment and Its Effect on Tumor Angiogenesis].

Sflt-1 Gene Therapy of Follicular Thyroid Carcinoma

A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Efficiently Inhibits Growth of VX2 Cells and VX2 Tumor Model of Hepatocellular Carcinoma in Rabbit by Transarterial Embolization-Mediated Sirna Delivery.

In Vivo Inhibition of Tumor Angiogenesis by A Soluble Vegfr-2 Fragment

AAV8-mediated sVEGFR2 and sVEGFR3 gene therapy combined with chemotherapy reduces the growth and microvasculature of human ovarian cancer and prolongs the survival in mice

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

Inhibiting Colorectal Carcinoma Growth and Metastasis by Blocking the Expression of Vegf Using Rna Interference

Inhibition of K562 Leukemia Angiogenesis and Growth by Expression of Antisense Vascular Endothelial Growth Factor (VEGF) Sequence

Inhibitory Effects of VEGF-siRNA Mediated by Adenovirus on Osteosarcoma-Bearing Nude Mice

[Inhibition of Bladder Cancer Cell Growth and Angiogenesis by Co-Blockage of Vascular Endothelial Growth Factor and Its Receptor KDR].

Sklb1002, A Novel Inhibitor of Vegf Receptor 2 Signaling, Induces Vascular Normalization to Improve Systemically Administered Chemotherapy Efficacy

Expression of Soluble Vascular Endothelial Growth Factor Receptor-2 and Its Effect on Proliferation of Vascular Endothelial Cells

RNA interference targeting EGFR on proliferation of human ovarian carcinoma cell line SKOV_3

Preclinical Safety, Toxicology, and Biodistribution Study of Adenoviral Gene Therapy with sVEGFR-2 and sVEGFR-3 Combined with Chemotherapy for Ovarian Cancer